Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1991 Jan;35(1):14–19. doi: 10.1128/aac.35.1.14

Antibacterial activities in vitro and in vivo and pharmacokinetics of cefquinome (HR 111V), a new broad-spectrum cephalosporin.

M Limbert 1, D Isert 1, N Klesel 1, A Markus 1, K Seeger 1, G Seibert 1, E Schrinner 1
PMCID: PMC244934  PMID: 2014969

Abstract

Cefquinome is a new injectable aminothiazolyl cephalosporin derivative. It is stable against chromosomally and plasmid-encoded beta-lactamases and has a broad antibacterial spectrum. Staphylococcus aureus, streptococci, Pseudomonas aeruginosa, and members of the family Enterobacteriaceae (Escherichia coli, Salmonella spp., Klebsiella spp., Enterobacter spp., Citrobacter spp., and Serratia marcescens) are inhibited at low concentrations. Cefquinome is also active against many strains of methicillin-resistant staphylococci and enterococci. Its in vitro activity against gram-negative anaerobes is very limited. The high in vitro activity of cefquinome is reflected by its high in vivo efficacy against experimental septicemia due to different gram-positive and gram-negative bacteria. We studied the pharmacokinetic properties of cefquinome in mice, dogs, pigs, and calves. After single parenteral administrations, cefquinome displayed high peak levels, declining with half-lives of about 0.5, 0.9, 1.2, and 1.3 h, respectively. The areas under the concentration-time curve determined for dogs and mice showed linear correlations to the given doses. In dogs the urinary recovery was more than 70% within 24 h of dosing.

Full text

PDF
14

Images in this article

16Image
on p.16

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Caprile K. A. The cephalosporin antimicrobial agents: a comprehensive review. J Vet Pharmacol Ther. 1988 Mar;11(1):1–32. doi: 10.1111/j.1365-2885.1988.tb00117.x. [DOI] [PubMed] [Google Scholar]
  2. Clarke A. M., Zemcov S. J., Wright J. M. HR 810 and BMY-28142, two new cephalosporins with broad-spectrum activity: an in-vitro comparison with other beta-lactam antibiotics. J Antimicrob Chemother. 1985 Mar;15(3):305–310. doi: 10.1093/jac/15.3.305. [DOI] [PubMed] [Google Scholar]
  3. Jones R. N., Gerlach E. H. Antimicrobial activity of HR810 against 419 strict anaerobic bacteria. Antimicrob Agents Chemother. 1985 Mar;27(3):413–415. doi: 10.1128/aac.27.3.413. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Jones R. N., Thornsberry C., Barry A. L. In vitro evaluation of HR810, a new wide-spectrum aminothiazolyl alpha-methoxyimino cephalosporin. Antimicrob Agents Chemother. 1984 Jun;25(6):710–718. doi: 10.1128/aac.25.6.710. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Klesel N., Limbert M., Schrinner E., Seeger K., Seibert G., Winkler I. Chemotherapeutic properties of the new cephalosporin antibiotic HR810 in laboratory animals. Infection. 1984 Jul-Aug;12(4):286–292. doi: 10.1007/BF01645963. [DOI] [PubMed] [Google Scholar]
  6. Neu H. C. Good antimicrobial prescribing. Clinical uses of cephalosporins. Lancet. 1982 Jul 31;2(8292):252–255. doi: 10.1016/s0140-6736(82)90333-6. [DOI] [PubMed] [Google Scholar]
  7. Richmond M. H. beta-Lactamase stability of cefotaxime. J Antimicrob Chemother. 1980 Sep;6 (Suppl A):13–17. doi: 10.1093/jac/6.suppl_a.13. [DOI] [PubMed] [Google Scholar]
  8. Ross G. W., O'Callaghan C. H. Beta-lactamase assays. Methods Enzymol. 1975;43:69–85. doi: 10.1016/0076-6879(75)43081-6. [DOI] [PubMed] [Google Scholar]
  9. Seibert G., Klesel N., Limbert M., Schrinner E., Seeger K., Winkler I., Lattrell R., Blumbach J., Dürckheimer W., Fleischmann K. HR 810, a new parenteral cephalosporin with a broad antibacterial spectrum. Arzneimittelforschung. 1983;33(8):1084–1086. doi: 10.1002/chin.198350201. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES